FDA: Genitope must continue vaccine tests

Genitope's hopes of bringing its MyVax cancer vaccine to market quickly were dashed Monday when an independent board recommended that a clinical trial of its cancer vaccine continue. Although the 300-patient trial was scheduled to end in 2007, Genitope believed its vaccine might produce results sooner. The vaccine for an incurable form of non-Hodgkin's lymphoma, a blood cancer, is Genitope's most advanced product. The news took a bite out of its stock value this morning.

- read this story from the Los Angeles Times for more

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.